RAF1 and cancer: Thus, preventing RAF dimerization is an effective strategy for the development of inhibitors with improved safety and durable efficacy and could provide clinical benefits to patients with cancer driven by not only BRAF mutations but also RAS mutations on the BRAF-wildtype background.